Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer

Immune-related adverse events, including autoimmune toxicity, may develop as a consequence of immune-checkpoint inhibitor (ICI) cancer therapy. Cytokine release syndrome (CRS) is a severe and life-threatening cytokine-associated toxicity that can develop after adoptive T-cell therapy. We herein repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yomota, Makiko, Mirokuji, Kie, Sakaguchi, Masahiro, Kitahara, Yasuyuki, Chin, Fangyi, Setoguchi, Keigo, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627810/
https://www.ncbi.nlm.nih.gov/pubmed/33775995
http://dx.doi.org/10.2169/internalmedicine.5922-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627810/
https://www.ncbi.nlm.nih.gov/pubmed/33775995
http://dx.doi.org/10.2169/internalmedicine.5922-20

Ejemplares similares